Cyteir Therapeutics is a clinical-stage oncology company that specializes in developing innovative solutions for cancer treatment. Their primary focus is on the development of CYT-0851, an oral investigational drug that targets monocarboxylate transporters. One of Cyteir's current priorities is the combination of CYT-0851 with capecitabine and gemcitabine in a Phase 1/2 clinical study.

This study specifically targets patients with advanced ovarian cancer, aiming to provide them with effective treatment options. With a pipeline of novel drug candidates, Cyteir is dedicated to addressing key vulnerabilities in cancer cells. Their goal is to develop breakthrough therapies that can significantly improve patient outcomes and quality of life.

Located in Lexington, Massachusetts, Cyteir is committed to advancing cancer research and providing hope to patients. They prioritize patient participation and encourage enrollment in their Phase 1/2 trial for advanced ovarian cancer. As a leader in the field, Cyteir aims to make a meaningful impact in the fight against cancer.

Their dedication, expertise, and innovative approach set them apart, making them a trusted name in the oncology community